Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

PFE

Pfizer – Analyzing the Latest Market Sentiment

This afternoon we watched Pfizer rise 7.0% to a price of $25.53 per share. The Large-Cap Pharmaceutical company is now trading -11.68% below its average target price of $28.9. Analysts have set target prices ranging from $24.0 to $36.0 per share for Pfizer, and have given the stock an average rating of buy.

Pfizer's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.0%. The stock's short ratio is 2.85. At 0.07%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.

Another number to watch is the company's rate of institutional share ownership, which now stands at 67.1%. In conclusion, we believe there is mixed market sentiment regarding Pfizer.

Institutions Invested in Pfizer

Date Reported Holder Percentage Shares Value
2025-06-30 Vanguard Group Inc 9% 533,363,457 $13,611,488,566
2025-06-30 Blackrock Inc. 9% 494,877,296 $12,629,317,903
2025-06-30 State Street Corporation 5% 296,301,310 $7,561,638,954
2025-06-30 Geode Capital Management, LLC 2% 127,471,481 $3,253,084,896
2025-06-30 NORGES BANK 2% 93,653,338 $2,390,042,517
2025-06-30 Wellington Management Group, LLP 1% 77,003,539 $1,965,137,987
2025-06-30 Massachusetts Financial Services Co. 1% 75,474,322 $1,926,112,217
2025-06-30 Morgan Stanley 1% 70,135,308 $1,789,860,048
2025-06-30 Northern Trust Corporation 1% 63,150,632 $1,611,610,420
2025-06-30 State Farm Mutual Automobile Insurance Co 1% 54,508,560 $1,391,063,882
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS